Biopharmaceutical company Dimerix Ltd (ASX:DXB) has launched a collaboration with a research network at the University of Michigan to facilitate recruitment and biomarker profiling across the United States for Phase 3 of its ACTION3 study.
The ACTION3 study aims to determine the safety and efficacy of drug candidate DMX-200 for the treatment of rare kidney condition Focal Segmental Glomerulosclerosis (FSGS); Dimerix hopes working with the university’s NEPTUNE Match study will provide a new source of patient referrals for this.
In total, the company is hoping to recruit 286 patients from around the world who have FSGS, with interim analysis to begin once the first 144 patients achieve 35 weeks of treatment – a milestone which Dimerix wants to reach by mid-2025.
NEPTUNE – a leading network for precision medicine in glomerular diseases (those affecting the kidney’s filtering units) – has a wide scope, having enrolled more than 1,100 participants from 32 sites over the past 16 years.
Crucially, biomarker profiling among Neptune Match participants is expected to aid in identifying patients with FSGS who meet the applicable (inclusion/exclusion) criteria and could benefit from a treatment type such as DMX-200.
Dimerix’s chief medical officer Dr David Fuller said the relationship between the two entities was significant.
“This is an extremely important collaboration for the ACTION3 trial as NEPTUNE is the recognised global leader in rare kidney disease research,” he said.
“The Neptune Match program has a track record of successfully assisting recruitment into trials and should boost our recruitment rate for the ACTION3 trial in the USA while the biomarker work will provide further invaluable insights into the mechanism of action and response to DMX-200 in patients with FSGS.”
At 16:06 AEDT, Dimerix was trading at 39.5 cents – a fall of 1.25% since the market opened.
Join the discussion: See what HotCopper users are saying about Dimerix and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
